SomnoMed Limited

ASX:SOM Stock Report

Market Cap: AU$91.8m

SomnoMed Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Amrita Blickstead

Chief executive officer

AU$624.3k

Total compensation

CEO salary percentage26.7%
CEO tenure4.3yrs
CEO ownership0.5%
Management average tenure5.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 02
SomnoMed Limited (ASX:SOM) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

Oct 16
Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Jul 15
SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

May 31
SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 15
SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Mar 04
SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

Dec 21
Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Sep 02
SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Jun 19
Is SomnoMed (ASX:SOM) Using Too Much Debt?

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

Nov 18
It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Sep 27
SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

May 10
Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Oct 26
Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

May 12
Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Mar 02
Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Feb 01
Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Dec 28
Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Dec 01
Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

Jul 28
Analysts Just Published A Bright New Outlook For SomnoMed Limited's (ASX:SOM)

SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

Jul 14
SomnoMed Limited (ASX:SOM) Insiders Increased Their Holdings

CEO Compensation Analysis

How has Amrita Blickstead's remuneration changed compared to SomnoMed's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$624kAU$167k

-AU$12m

Mar 31 2024n/an/a

-AU$11m

Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$9m

Jun 30 2023AU$91kn/a

-AU$8m

Mar 31 2023n/an/a

-AU$7m

Dec 31 2022n/an/a

-AU$5m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022AU$91kn/a

-AU$4m

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$5m

Sep 30 2021n/an/a

-AU$3m

Jun 30 2021AU$32kn/a

-AU$1m

Compensation vs Market: Amrita's total compensation ($USD390.47K) is above average for companies of similar size in the Australian market ($USD291.28K).

Compensation vs Earnings: Amrita's compensation has increased whilst the company is unprofitable.

CEO

Amrita Blickstead

4.3yrs

Tenure

AU$624,323

Compensation

Ms. Amrita Blickstead, MBA, BME, is Co-Chief Executive Officer and Executive Director of SomnoMed Limited. Ms. Blickstead was Non-Executive Director of SomnoMed Limited from August 24, 2020. Ms. Blickstead...

Leadership Team

NamePositionTenureCompensationOwnership
Amrita Blickstead
Co-CEO & Executive Directorno dataAU$624.32k0.49%
A$ 453.6k
Karen Borg
Co-CEO & Executive Directorno dataAU$693.50k0.24%
A$ 218.5k
Mark Harding
Vice President of Global Marketing5.4yrsAU$483.37k0.067%
A$ 61.5k
Matthew Conlon
Executive VP of Sales & Marketing - North America5.2yrsAU$427.31kno data
Marco Van Kleef
Vice President of Marketing & Sales - Europeno dataAU$589.17kno data
Ye-Fei Guo
Chief Financial Officerless than a yearno datano data
Terence Flitcroft
Company Secretary29.9yrsAU$10.56kno data
Christopher Bedford
Vice President of Global Production and Product Developmentno dataAU$128.07kno data

5.3yrs

Average Tenure

Experienced Management: SOM's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Amrita Blickstead
Co-CEO & Executive Director4.3yrsAU$624.32k0.49%
A$ 453.6k
Karen Borg
Co-CEO & Executive Director4.1yrsAU$693.50k0.24%
A$ 218.5k
Michael Gordon
Non-Executive Director4.3yrsAU$92.38k0.10%
A$ 95.6k
Iven Klineberg
Member of the Medical Advisory Boardno datano datano data
J. Gerschman
Member of the Medical Advisory Boardno datano datano data
Peter Cistulli
Chairman of the Medical Advisory Boardno datano datano data
Gaetano Russo
Chairman of the Board4.3yrsAU$160.96k0.95%
A$ 873.5k
Benjamin Gisz
Non-Executive Directorless than a yearno datano data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Board: SOM's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:29
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SomnoMed Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Peter MeichelboeckSelect Equities Pty Ltd
Dr StoreyWilsons Advisory and Stockbroking Ltd.